NCRI 2021 | SELIMETRY: Resensitizing thyroid cancer to radioiodine therapy with selumetinib

Jon Wadsley, MB, BChir, MA, MRCP, FRCR, Weston Park Cancer Centre, Sheffield, UK, presents results from the Phase II multicenter SELIMETRY trial (EudraCT No 2015-002269-47), which aimed to assess the efficacy of selumetinib in resensitizing thyroid cancer to radioiodine therapy. The primary endpoint of progression free survival (PFS) was not sufficiently met as a smaller than expected proportion of patients who were successfully resensitized to radioiodine therapy was reported. Prof. Wadsley additionally discusses how the study group measured the dose of the radioiodine therapy by performing a pretreatment scan. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.